Vitamin E (α-tocopherol) to reduce inflammation and symptoms in rheumatoid arthritis
Official title: "Evaluation of the Effect of Vitamin E (α-tocopherol) Supplementation on Clinical Activity and Inflammation in Patients With Rheumatoid Arthritis"
Run by University of Guadalajara · NCT06915701 · Data updated 2026-11-12
This project will test whether taking vitamin E every day for one month reduces inflammation and joint symptoms in adults with early rheumatoid arthritis who have low vitamin E intake.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 46 (estimated) |
| Sponsor | University of Guadalajara Academic / other |
| Locations | 2 sites (Guadalajara, Jalisco and 1 other locations) |
| Status | Recruiting |
| Started | February 6, 2026 |
| Main results expected | December 15, 2026 |
| Study ends | January 15, 2027 |
| Registry record updated | February 13, 2026 |
| Trial ID | NCT06915701 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult women with early (≤2 years) rheumatoid arthritis, active disease (DAS28 ≥ 3.2), low dietary vitamin E intake (<15 mg/day), on conventional synthetic DMARD therapy, without comorbidities, and willing to consent are ideal candidates.
✕Probably not a fit
Men, patients with significant comorbidities, those already taking vitamin E or excluded medications or supplements, pregnant individuals, and people with longer-standing or more complex RA are unlikely to benefit from this specific protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Adults with early rheumatoid arthritis who meet eligibility criteria will be assigned to take either 800 mg/day α-tocopherol (two capsules) or a matching placebo for one month while continuing their conventional synthetic disease-modifying drugs. Clinic visits are scheduled at baseline and after one month for clinical exams and blood tests, and participants will keep a daily symptom and dosing diary. The main outcomes are changes in clinical disease activity (DAS28) and inflammatory markers. The trial is conducted at the University of Guadalajara and the Civil Hospital of Guadalajara.
Why it matters
Potential benefit: If effective, short-term vitamin E supplementation could lower joint inflammation and disease activity, improving symptoms for some patients with early rheumatoid arthritis.
How similar studies have gone: Animal studies and a few small clinical trials have reported reductions in inflammatory markers and clinical activity with α-tocopherol, but overall human evidence is limited and mechanisms remain unclear.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion criteria: * Female sex * RA classification (ACR/EULAR 2010) * Early RA 2 years * Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina and their combinations) * DAS28 ≥3.2 * Vitamin E intake deficiency (\<15mg/day) * No comorbidities * Age \> 18 years * Voluntary participation and informed consent. Exclusion Criteria: * Liver and kidney disease * Overlap syndrome * Coagulation disorders * Pregnancy * Consumption of supplements (iron, vitamin E, and K), and medications such as acetylsalicylic acid, amlodipine, estrogen, glucocorticoids and drugs used to treat dyslipidemias in the last three months. Elimination Criteria: * Errors in administration of the 20% supplement * Adverse effects of the supplement * Pregnancy during the study * Insufficient blood sample * Voluntary withdrawal of informed consent.
Where it's running
-
Civil Hospital of Guadalajara
Guadalajara, Jalisco, Mexico Recruiting -
Universidad de Guadalajara
Guadalajara, Jalisco, Mexico Not yet recruiting
Study contacts
- Principal investigator: Christian Johana J Baños Hernández, D.Sc. — University of Guadalajara
- Study coordinator: Christian Johana J Baños Hernández, D.Sc.
- Email: johana.banos@academicos.udg.mx
- Phone: +54 10585200 ó 7471493487
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
GenAI-assisted RA bone erosion risk and DMARD choice
This study tests whether GenAI-based decision support can help doctors assess rheumatoid arthritis bone erosion risk and pick DMARDs for newly diagnosed inpatients.
-
Pain patterns in rheumatic diseases: see if pain works differently in patients and healthy people
This observational study tests how pain is experienced and measured in people with rheumatic diseases compared with healthy volunteers.
-
Telitacicept for difficult-to-treat rheumatoid arthritis
This study tests whether adding telitacicept to standard therapy helps adults with hard-to-treat rheumatoid arthritis see better control of their symptoms.
-
PTC844 in people with active rheumatoid arthritis
This study tests whether PTC844 is safe and how it behaves in the body compared with placebo for people with active rheumatoid arthritis.
-
First-in-human test of CND319 in healthy people and people with rheumatic diseases
This early study tests whether CND319 is safe and tolerable and whether it shows any signs of activity in healthy adults and in people with rheumatoid arthritis or Sjogren's syndrome.
-
IV sarilumab for adults with rheumatoid arthritis
This study tests IV sarilumab to see how it works and how safe it is for adults with moderately to severely active rheumatoid arthritis, with or without certain standard arthritis medicines.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.